

**Reference Number:** FOI202223/140  
**From:** Private Individual  
**Date:** 23 June 2022  
**Subject:** Antifungal treatment

- Q1 What is the number of patients in the last 12 months treated with the following product lines:
1. anidulafungin
  2. caspofungin
  3. micafungin
- A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q2 What is the split of indication over the last 12 months for the following product lines:
1. anidulafungin
  2. caspofungin
  3. micafungin
- A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q3 For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2) list the average length of treatment time.
- A3 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.